نتایج جستجو برای: intranasal corticosteroid

تعداد نتایج: 21582  

Journal: :The Journal of asthma : official journal of the Association for the Care of Asthma 2007
Kenneth Kim Javier Quesada Nancy Szmaydy-Rikken Patrick Darken Tushar Shah

Intranasal and inhaled corticosteroid administration concurrently in comorbid allergic rhinitis (AR) and asthma may potentially enhance cortisol suppression. This study determined whether intranasal ciclesonide 200 micro g once daily has an additional effect on cortisol suppression when coadministered with inhaled fluticasone propionate-salmeterol (FP-SAL) 500 to 50 micro g twice daily. Adults ...

Journal: :Archives of otolaryngology--head & neck surgery 2003
Desiderio Passàli Joel M Bernstein Francesco Maria Passali Valerio Damiani Giulio Cesare Passàli Luisa Bellussi

OBJECTIVE To demonstrate the long-term efficacy of intranasal furosemide, an inhibitor of the sodium chloride cotransporter channel at the basolateral surface of the respiratory epithelial cell, vs no therapeutic intervention vs intranasal mometasone furoate, a corticosteroid, in preventing relapses of chronic hyperplastic sinusitis with nasal polyposis. DESIGN Randomized prospective controll...

Journal: :Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2010
Manabu Nonaka Atsuko Sakanushi Kaoru Kusama Nozomu Ogihara Toshiaki Yagi

OBJECTIVES Chronic rhinosinusitis associated with asthma is often difficult to treat effectively with intranasal corticosteroids alone. Thus, the aim of this study was to evaluate the effectiveness of combination treatment with an intranasal corticosteroid and a leukotriene-receptor antagonist (montelukast) in reducing the size of nasal polyps. METHODS The subjects of this study were 20 patie...

2014
Claus Bachert

• Currently considered first-line allergic rhinitis (AR) therapy provides insufficient symptom relief for many AR patients. • MP29-02 (Dymista®, Meda AB, Solna, Sweden) is a new intranasal AR therapy, consisting of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel and patented formulation and advanced device. • It is indicated for the symptomatic relief of moderate/sever...

Journal: :Therapeutics and Clinical Risk Management 2008
Pedro Giavina-Bianchi Rosana Agondi Rafael Stelmach Alberto Cukier Jorge Kalil

Allergic rhinitis (AR) is a prevalent disease with great morbidity and significant societal and economic burden. Intranasal corticosteroids are recommended as first-line therapy for patients with moderate-to-severe disease, especially when nasal congestion is a major component of symptoms. To compare the efficacy and safety profile of different available intranasal corticosteroids for the treat...

Journal: :Allergy and asthma proceedings 2011
Jison Hong Brett Bielory J Loren Rosenberg Leonard Bielory

Current treatment options for allergic rhinoconjunctivitis include topical antihistamines, vasoconstrictors, mast cell stabilizers, intranasal corticosteroids (INCS), and nonsteroidal anti-inflammatory drugs that are generally used as a supplement to oral or intranasal therapies, necessitating the use of multiple treatments for the different symptoms of allergic rhinitis (AR). To assess the eff...

Journal: :Archives of internal medicine 2001
S M Kaszuba F M Baroody M deTineo L Haney C Blair R M Naclerio

BACKGROUND The daily use of either intranasal corticosteroids or histamine(1) (H(1)) receptor antagonists has proved to be efficacious in the treatment of seasonal allergic rhinitis. Most patients, however, use these medications as needed. Our objective was to compare the effectiveness of as-needed use of H(1) receptor antagonists with that of intranasal corticosteroids in the treatment of seas...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید